Evidence map›Paper›PMID 40565143›Full record

ArticleInternational journal of molecular sciences2025

Genetic Variants in Oxidative Stress-Related Genes and Their Impact on Prognosis and Treatment Response in Chronic Myeloid Leukemia Patients.

Raquel Alves, Filipa Ventura, Joana Jorge, Gilberto Marques, Margarida Coucelo, Joana Diamond, Bárbara Oliveiros, Amélia Pereira, Paulo Freitas-Tavares, António M Almeida and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. ROS and Antioxidants: Prospective Therapeutic Options in Cancer.Journal of cellular and molecular medicine · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Raquel AlvesLaboratory of Oncobiology and Hematology (LOH) and University Clinics of Hematology and Oncology, Faculty of Medicine University of Coimbra (FMUC), University of Coimbra, 3000-548 Coimbra, Portugal.ORCID 0000-0003-2599-6433
Filipa VenturaLaboratory of Oncobiology and Hematology (LOH) and University Clinics of Hematology and Oncology, Faculty of Medicine University of Coimbra (FMUC), University of Coimbra, 3000-548 Coimbra, Portugal.
Joana JorgeLaboratory of Oncobiology and Hematology (LOH) and University Clinics of Hematology and Oncology, Faculty of Medicine University of Coimbra (FMUC), University of Coimbra, 3000-548 Coimbra, Portugal.ORCID 0000-0003-0755-8077
Gilberto MarquesClinical Pathology Service, Centro Hospitalar Universitário de Coimbra (CHUC), 3000-061 Coimbra, Portugal.
Margarida CouceloCoimbra Institute for Clinical and Biomedical Research (iCBR)-Group of Environmental Genetics of Oncobiology (CIMAGO), Faculty of Medicine University of Coimbra (FMUC), University of Coimbra, 3000-548 Coimbra, Portugal.ORCID 0000-0002-3426-6363
Joana DiamondHemato-Oncology Laboratory, Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, 1099-023 Lisbon, Portugal.
Bárbara OliveirosCoimbra Institute for Clinical and Biomedical Research (iCBR)-Group of Environmental Genetics of Oncobiology (CIMAGO), Faculty of Medicine University of Coimbra (FMUC), University of Coimbra, 3000-548 Coimbra, Portugal.ORCID 0000-0001-7836-8161
Amélia PereiraCoimbra Institute for Clinical and Biomedical Research (iCBR)-Group of Environmental Genetics of Oncobiology (CIMAGO), Faculty of Medicine University of Coimbra (FMUC), University of Coimbra, 3000-548 Coimbra, Portugal.
Paulo Freitas-TavaresOrthopedic Oncology Department, Centro Hospitalar Universitário de Coimbra (CHUC), 3000-061 Coimbra, Portugal.ORCID 0000-0001-7832-4134
António M AlmeidaHospital da Luz Lisboa, 1500-650 Lisbon, Portugal.
Ana Cristina GonçalvesLaboratory of Oncobiology and Hematology (LOH) and University Clinics of Hematology and Oncology, Faculty of Medicine University of Coimbra (FMUC), University of Coimbra, 3000-548 Coimbra, Portugal.ORCID 0000-0003-1470-4802
Ana Bela Sarmento-RibeiroLaboratory of Oncobiology and Hematology (LOH) and University Clinics of Hematology and Oncology, Faculty of Medicine University of Coimbra (FMUC), University of Coimbra, 3000-548 Coimbra, Portugal.ORCID 0000-0002-4142-4841

Funding

Fundação para a Ciência e Tecnologia LA/P/0058/2020 (10.54499/LA/P/0058/2020)Fundação para a Ciência e Tecnologia UIDB/04539/2020 (10.54499/UIDB/04539/2020) and UIDP/04539/2020 (10.54499/UIDP/04539/2020)Liga Portuguesa Contra o Cancro CIMAGO (Project 18/12)
6 · The paper itself

Abstract

Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasia characterized by the

Indexed as

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveOxidative StressPolymorphism, Single NucleotideAdultAgedAged, 80 and overCatalaseDrug Resistance, NeoplasmFemaleFusion Proteins, bcr-ablGenotypeGlutathione PeroxidaseGlutathione Peroxidase GPX1HumansKelch-Like ECH-Associated Protein 1MaleCatalaseFusion Proteins, bcr-ablGlutathione PeroxidaseGlutathione Peroxidase GPX1GPX1 protein, humanKEAP1 protein, humanKelch-Like ECH-Associated Protein 1NFE2L2 protein, humanNF-E2-Related Factor 2Protein Kinase InhibitorsSuperoxide DismutaseSuperoxide Dismutase 2antioxidant defenseschromic myeloid leukemiagenetic variantsNRF2/KEAP1 pathwayoverall survivaltyrosine kinase inhibitor resistance

Identifiers

PMID40565143
PMCPMC12193163

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.